Efficacy and safety of deflazacort in diabetic subjects infected with SARS-CoV-2.

IF 1.6 Q3 RESPIRATORY SYSTEM

Multidisciplinary Respiratory Medicine Pub Date : 2025-10-03 DOI:10.5826/mrm.2025.1035

Claudio Ucciferri, Alessandro Di Gasbarro, Jacopo Vecchiet, Katia Falasca

{"title":"Efficacy and safety of deflazacort in diabetic subjects infected with SARS-CoV-2.","authors":"Claudio Ucciferri, Alessandro Di Gasbarro, Jacopo Vecchiet, Katia Falasca","doi":"10.5826/mrm.2025.1035","DOIUrl":null,"url":null,"abstract":"Background: Different therapies are recommended for the management of COVID-19 at home, use of steroids is the reference for the home management of COVID-19 in second phase of the disease. Several steroids are recommended in the treatment of COVID-19; however, the use of steroids is known to bring to problems in the management of diabetic patients.Methods: This is a retrospective observational study, conducted with the aim of evaluating the efficacy and safety of the administration of deflazacort in diabetic outpatients infected with SARS-CoV-2, versus standard use of dexamethasone/methylprednisolone.Results: A total of 63 patients were enrolled: 15 in the \"deflazacort\" group and 48 in the \" dexamethasone/-methylprednisolone \" group. The study population was 49.2% male with a median age of 63.6 years (IQR 54.5-71.0). 44 (69.8%) patients had at least one comorbidity in addition to diabetes. A total of 4 (6.3%) patients (50% females) required hospital care for glycaemic decompensation, all in the dexamethasone/methylprednisolone group (0 vs 4 p=0.019). Hospitalization occurred in 19 (30.1%) for respiratory failure related to SARS-CoV-2 infection: 5 in the deflazacort group, 14 in the dexamethasone/methylprednisolone group (p=0.76) The mean number of days between illness onset and the first negative swab was 28.4 days in the deflazacort group and 27.4 days in the dexamethasone/methylprednisolone group (p=0.40).Conclusion: Deflazacort demonstrated a lower incidence of hospital admission for glycaemic decompensation compared to standard treatment with dexamethasone/methylprednisolone in SARS-CoV-2 positive outpatients. There were no differences in COVID-19-related hospitalizations between the two groups.","PeriodicalId":51135,"journal":{"name":"Multidisciplinary Respiratory Medicine","volume":"20 ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multidisciplinary Respiratory Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5826/mrm.2025.1035","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Different therapies are recommended for the management of COVID-19 at home, use of steroids is the reference for the home management of COVID-19 in second phase of the disease. Several steroids are recommended in the treatment of COVID-19; however, the use of steroids is known to bring to problems in the management of diabetic patients.

Methods: This is a retrospective observational study, conducted with the aim of evaluating the efficacy and safety of the administration of deflazacort in diabetic outpatients infected with SARS-CoV-2, versus standard use of dexamethasone/methylprednisolone.

Results: A total of 63 patients were enrolled: 15 in the "deflazacort" group and 48 in the " dexamethasone/-methylprednisolone " group. The study population was 49.2% male with a median age of 63.6 years (IQR 54.5-71.0). 44 (69.8%) patients had at least one comorbidity in addition to diabetes. A total of 4 (6.3%) patients (50% females) required hospital care for glycaemic decompensation, all in the dexamethasone/methylprednisolone group (0 vs 4 p=0.019). Hospitalization occurred in 19 (30.1%) for respiratory failure related to SARS-CoV-2 infection: 5 in the deflazacort group, 14 in the dexamethasone/methylprednisolone group (p=0.76) The mean number of days between illness onset and the first negative swab was 28.4 days in the deflazacort group and 27.4 days in the dexamethasone/methylprednisolone group (p=0.40).

Conclusion: Deflazacort demonstrated a lower incidence of hospital admission for glycaemic decompensation compared to standard treatment with dexamethasone/methylprednisolone in SARS-CoV-2 positive outpatients. There were no differences in COVID-19-related hospitalizations between the two groups.

查看原文本刊更多论文

地沙库特对糖尿病患者SARS-CoV-2感染的疗效和安全性。

背景：COVID-19的家庭管理推荐不同的治疗方法，类固醇的使用是COVID-19第二阶段疾病家庭管理的参考。推荐使用几种类固醇治疗COVID-19；然而，已知使用类固醇会给糖尿病患者的管理带来问题。方法：本研究是一项回顾性观察性研究，目的是评估地塞米松/甲基强的松龙对感染SARS-CoV-2的糖尿病门诊患者给予地拉法柯与标准使用地塞米松/甲泼尼龙的疗效和安全性。结果：共纳入63例患者：“地拉法柯”组15例，“地塞米松/-甲基强的松龙”组48例。研究人群中男性占49.2%，中位年龄为63.6岁（IQR为54.5-71.0）。44例（69.8%）患者除糖尿病外至少有一种合并症。共有4例（6.3%）患者（50%为女性）因血糖失代偿需要住院治疗，均为地塞米松/甲基强的松龙组（0 vs 4 p=0.019）。因SARS-CoV-2感染相关呼吸衰竭住院19例（30.1%）：地拉沙柯组5例，地塞米松/甲基强的松龙组14例（p=0.76）。地拉沙柯组发病至首次拭子阴性的平均天数为28.4天，地塞米松/甲基强的松龙组27.4天（p=0.40）。结论：在SARS-CoV-2阳性门诊患者中，与地塞米松/甲基强的松龙标准治疗相比，地拉法柯因血糖失代偿住院的发生率较低。两组之间与covid -19相关的住院治疗没有差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Multidisciplinary Respiratory Medicine 医学-呼吸系统

CiteScore

4.40

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Multidisciplinary Respiratory Medicine is the official journal of the Italian Respiratory Society - Società Italiana di Pneumologia (IRS/SIP). The journal publishes on all aspects of respiratory medicine and related fields, with a particular focus on interdisciplinary and translational research. The interdisciplinary nature of the journal provides a unique opportunity for researchers, clinicians and healthcare professionals across specialties to collaborate and exchange information. The journal provides a high visibility platform for the publication and dissemination of top quality original scientific articles, reviews and important position papers documenting clinical and experimental advances.